TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Six month history of migraine; attacks typically mild when they begin with 1-4 migraine attacks per month.~Exclusion Criteria:~* Heart disease~* High blood pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal patients with various chronic rheumatic diseases receiving chronic steroid therapy.~2. Stable disease for at least 6 months prior to study with a stable dose of steroid (prednisone \<= 10 mg/day or equivalent).~3. Baseline bone mineral density (BMD) of the lumbar spine T score \< -1.0.~Exclusion Criteria:~1. Patients with a history of thromboembolism.~2. Patients with positive antiphospholipid antibodies.~3. History of allergic reactions or intolerance to raloxifene or other SERMs.~4. Patients receiving bisphosphonates, parathyroid hormone, SERMs, anticonvulsants or anti-cytokine therapies within 6 months prior to study entry.~5. Patients with known bone disorders such as osteomalacia, renal osteodystrophy, and hyperparathyroidism.~6. Patients with abnormal uterine bleeding of unknown etiology.~7. Patients with serum creatinine level of \>= 200 umol/L.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): raloxifene
- 2 (Type: PLACEBO_COMPARATOR): placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the HGS1006-C1056 protocol in the United States through Week 72 visit.~* Be able to receive 1st dose of belimumab for HGS 1006-c1066 four weeks after last dose in HGS1006-c1056.~Exclusion Criteria:~* Have developed any other medical disease or condition that has made the subject unsuitable for this study in the opinion of their physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belimumab 1 mg/kg (Type: EXPERIMENTAL): Belimumab 1 mg/kg IV every 28 days
- Belimumab 10 mg/kg (Type: EXPERIMENTAL): Belimumab 10 mg/kg IV every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged ≥18 years of age~* CSU diagnosis for ≥ 6 months prior to screening~* Presence of itch and hives for ≥6 consecutive weeks prior to screening in spite of use of non-sedating H1-antihistamines according to local Treatment guidelines during this time period~* UAS7 score (range 0-42) ≥16 and HSS7 score (range 0-21) ≥ 8 during 7 days prior to randomization (Day 1)~* Willing and able to complete an Urticaria Participant Daily eDiary (UPDD) for the duration of the study~Exclusion Criteria:~* Hypersensitivity to any of the study treatments~* Clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria)~* Other diseases with symptoms of urticaria or angioedema~* Other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results,~* Known or suspected history of an ongoing, chronic or recurrent infectious disease including but not limited to opportunistic infections (eg tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis), HIV, Hepatitis B/C.~* Pregnant or nursing (lactating) women~* Women of child-bearing potential not using highly effective methods of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- LOU064 Arm 1 (Type: EXPERIMENTAL): 10 mg LOU064 qd capsule once daily
- LOU064 Arm 2 (Type: EXPERIMENTAL): 35 mg capsule qd LOU064 once daily
- LOU064 Arm 3 (Type: EXPERIMENTAL): 100 mg capsule qd LOU064 once daily
- LOU064 Arm 4 (Type: EXPERIMENTAL): 10 mg capsule LOU064 bid
- LOU064 Arm 5 (Type: EXPERIMENTAL): 25 mg capsule LOU064 bid
- LOU064 Arm 6 (Type: EXPERIMENTAL): 100 mg capsule LOU064 bid
- Placebo Arm (Type: PLACEBO_COMPARATOR): Participants took matching placebo twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory CLL and require treatment in opinion of investigator.~* Eastern Cooperative Oncology Group (ECOG) \<= 1.~* Adequate bone marrow independent of growth factor support, renal and hepatic function per defined laboratory criteria.~Exclusion Criteria:~* History or is clinically suspicious for cancer-related Central Nervous System disease.~* Receipt of allogenic or autologous stem cell transplant.~* Recent history (within 1 year of first dose) of underlying, predisposing condition of bleeding or currently exhibits signs of bleeding.~* Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis.~* Active immune thrombocytopenic purpura or history of being refractory to platelet transfusions (within 1 year of first dose).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Navitoclax 14/21 Day Cycle: 10 mg (Type: EXPERIMENTAL): Navitoclax 10 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
- Navitoclax 14/21 Day Cycle: 110 mg (Type: EXPERIMENTAL): Navitoclax 110 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
- Navitoclax 14/21 Day Cycle: 200 mg (Type: EXPERIMENTAL): Navitoclax 200 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
- Navitoclax 14/21 Day Cycle: 250 mg (Type: EXPERIMENTAL): Navitoclax 250 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
- Navitoclax 21/21 Day Cycle: 125 mg (Type: EXPERIMENTAL): Navitoclax 125 mg administered for 21 consecutive days to complete a 21-day cycle.
- Navitoclax 21/21 Day Cycle: 200 mg (Type: EXPERIMENTAL): Navitoclax 200 mg administered for 21 consecutive days to complete a 21-day cycle.
- Navitoclax 21/21 Day Cycle: 250 mg (Type: EXPERIMENTAL): Navitoclax 250 mg administered for 21 consecutive days to complete a 21-day cycle.
- Navitoclax 21/21 Day Cycle: 300 mg (Type: EXPERIMENTAL): Navitoclax 300 mg administered for 21 consecutive days to complete a 21-day cycle.
- Phase 2: Navitoclax 100 mg (Type: EXPERIMENTAL): Navitoclax 100 mg in participants with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).
- Phase 2: Navitoclax 250 mg (Type: EXPERIMENTAL): Navitoclax 250 mg in participants with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age at least 18 years.~* Provision of written, informed consent.~* Screening plasma HIV RNA \> 10,000 copies/mL.~* Screening CD4+ T lymphocyte count \> 100 x 10\^6)/L.~* No previous antiretroviral therapy.~* Haemoglobin \> 115 g/L (female) or \> 130 g/L (male).~* Absolute neutrophil count \> 1 x 10\^9/L.~* Platelet count \> 100 x 10\^9/L~* Serum bilirubin \< 1.5 x ULN.~* Serum alkaline phosphatase \< 3 X ULN.~* Serum aspartate aminotransferase (AST) \< 3 X ULN.~* Serum alanine aminotransferase (ALT) \< 3 X ULN.~* Creatinine clearance \> 50mL/min (Creatinine clearance (mL/min) =140 - age x weight creatinine Multiply the result by 1.2 for men).~Cohort A: Primary HIV infection:~Documented acute or early infection diagnosed by:~Acute infection:~\< 3 bands on Western Blot and any one of: i. positive p24 antigen ii. positive proviral DNA~Early infection:~i. Positive detuned or BED ELISA result OR ii. Previously negative serology within 6 months of confirmed positive serology.~Cohort B: Chronic HIV infection:~Documented HIV-infection of at least 12 months duration.~Exclusion Criteria:~* Pregnancy or breastfeeding.~* Receipt of investigational products within 1 month of study entry.~* Receipt of any of the following within 6 months of study entry:~  * interferon alpha or gamma~ * oral corticosteroids (inhaled or topical corticosteroids are permitted)~ * cyclosporin~ * alkylating agents~ * other immunosuppressive agents~ * rifampin~ * phenytoin~ * phenobarbital~* Documented genotypic (IAS 2007) resistance to tenofovir or emtricitabine from any HIV drug resistance test.~* Any medications contraindicated with Truvada or raltegravir.~* Significant intercurrent illnesses apart from HIV infection such as viral hepatitis (diagnosed by core hepatitis B antigen and/or positive hepatitis B PCR or positive hepatitis C PCR) or any other condition which in the opinion of the investigator would compromise participation in the study.~* History of non-traumatic osteoporotic fracture.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- antiretroviral therapy (Type: EXPERIMENTAL): tenofovir (TDF) + emtricitabine (FTC) as a fixed dose combination administered orally once per day and raltegravir (RAL) administered orally twice per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MSG Use With 18F-DCFPyL PET/CT Imaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known prostate cancer with biochemical recurrence after initial curative therapy with radical prostatectomy, presenting with a prostate specific antigen (PSA) greater than 0.4 ng/mL.~* Subjects with findings on other examinations (such as plain x-ray, CT, MRI or bone scintigraphy and others) that are suspicious for metastatic disease but not conclusively diagnostic of metastatic disease, within 3 months of PET scan.~* Known prostate cancer with biochemical recurrence after initial curative therapy with radiation therapy (including brachytherapy), with a PSA level \>2 ng/mL above the nadir after radiation therapy.~* Castration resistant prostate cancer with a minimum PSA of 2.0 ng/mL with 2 consecutive rises above the nadir and castrate levels of testosterone (\<1.7 nmol/L). Treatment does not need to be discontinued before the 18F-DCFPyL scan.~* Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.~Exclusion Criteria:~* Medically unstable (eg. acute illness, unstable vital signs)~* Unable to lie supine for the duration of imaging~* Unable to provide written consent~* Exceeds safe weight limit of the PET/CT bed (204.5 kg) or unable to fit through the PET/CT bore (diameter 70 cm)~* Severe uncontrolled hypertension (systolic blood pressure above 140 mm Hg and diastolic blood pressure above 90 mm Hg, or systolic blood pressure above 180 mm Hg, or diastolic blood pressure above 110 mg Hg). Patients with controlled hypertension under medication are eligible~* History of severe asthma that has led to hospitalizations or emergency room visits~* History of intolerance to MSG~* History of severe headaches or migraines triggered by food or MSG~* Participants on a sodium/salt restricted diet due to other medical conditions~* No new treatment has started between the first and second 18F-DCFPyL PET/CT

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18F-DCFPyL PET/CT scan with MSG drink (Type: EXPERIMENTAL): Food grade MSG will be dissolved in low sodium tomato juice, and administered orally before 18F-DCFPyL administration.
- 18F-DCFPyL PET/CT scan with placebo drink (Type: PLACEBO_COMPARATOR): Regular tomato juice will be used, and administered orally before 18F-DCFPyL administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Histologically confirmed and documented recurrent ovarian, fallopian tube, and peritoneal cancer.~* Platinum resistant disease, defined as progression within ≤ 6 months from completion of most recent regimen and calculated from the date of the last administered dose of platinum therapy~* Must have available archived tumor tissue OR if archived tissue is not available, willing to provide a fresh tumor biopsy~* Must have radiologic imaging with a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within 4 weeks of first dose of study drug~* Received at least 1 but not more than 3 therapy regimens, not including maintenance or adjuvant therapy~* Must have ovarian cancer that is measurable according to RECIST 1.1~* ECOG performance status of 0-1~* Normal gastrointestinal (GI), bone marrow, liver and kidney function~* At least 28 days between termination of prior anti-cancer or hormonal therapy and administration of AVB-S6-500~Exclusion Criteria:~* Primary platinum-refractory disease (defined as progression during the first platinum regimen or within 4 weeks of completion of the first platinum regimen)~* Currently being treated with concurrent anti-cancer therapy or any other interventional treatment or trial~* Received prior therapy with Pac or PLD in the recurrent setting, depending on physician-chosen chemotherapy for this study~* Significant cardiac disease history~* Has other prior or concurrent malignancy within the past 5 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix~* Symptomatic CNS metastasis or metastases~* Serious active infection requiring IV antibiotics and/or hospitalization at study entry~* Has known previous or current human immune deficiency (HIV) syndrome, hepatitis B, or hepatitis C~* Has had paracentesis for ascites within 3 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1b: AVB-S6-500+PLD (Type: EXPERIMENTAL): None
- Phase 1b: AVB-S6-500+Pac (Type: EXPERIMENTAL): None
- Phase 2: AVB-S6-500+PLD (Type: EXPERIMENTAL): None
- Phase 2: AVB-S6-500+Pac (Type: EXPERIMENTAL): None
- Phase 2: Placebo+PLD (Type: ACTIVE_COMPARATOR): None
- Phase 2: Placebo+Pac (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Automatic Oxygen Flow Titration During Walking in Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 40 years~* Moderate to severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease guidelines~* Who did not require long-term oxygen therapy were included in the study.~* Patients were also selected on the basis of known (end-exercise SpO2 \< 90% on a previous exercise test) or suspected (SpO2 \< 95% at rest) desaturation during exercise~Exclusion Criteria:~* Episode of exacerbation or hospitalisation within last four weeks~* Current medical condition that could influence exercise tolerance

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Compressed Air (Type: SHAM_COMPARATOR): compressed air delivered at a fixed flow of 2 L/min
- Oxygen constant flow (Type: ACTIVE_COMPARATOR): oxygen delivered at a fixed flow of 2L/min
- Automated oxygen titration (Type: EXPERIMENTAL): oxygen at a variable flows delivered by the FreeO2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Pre or perimenopausal at MBC diagnosis~2. Diagnosis of MBC in patient history~3. Confirmed HR+/HER2- status as defined as: a. HR+: ER+ or PR+ test; b. HER2-: any HER2 negative test and the absence of a positive test (IHC positive 3+, fluorescence in situ hybridization \[FISH\] positive/amplified, positive not otherwise specified \[NOS\]).~4. Received one of the following regimens as first-line treatment for MBC during the period from 01 January 2010 through index period 30 June 2020 until the data cutoff date of 31 December 2020.~   1. Palbociclib + AI as first-line treatment for MBC or~  2. Monotherapy AI as first-line treatment for MBC~5. Received care at a US Oncology Network (USON) site(s) utilizing the full EHR capacities of iKnowMed (iKM) at the time of treatment.~6. EHR data available from the USON site(s) where the patient received treatment are accessible for research purposes.~Exclusion Criteria:~1. Evidence of prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors (palbociclib, ribociclib or abemaciclib) in the early breast cancer (BC) or MBC setting.~2. First structured activity (clinical visit) greater than 120 days after MBC diagnostic date with chart review to confirm no initial MBC treatment outside USON.~3. Receipt of treatment indicated for another primary cancer during the study observation period (after initiation of Palbociclib + AI or AI monotherapy and before 31 December 2020) or history of another primary cancer within USON.~4. Enrolled in any interventional clinical trial after initiation of Palbociclib + AI or AI monotherapy AND before 31 December 2020.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palbociclib + aromatase inhibitor (Type: None): Palbociclib + aromatase inhibitor
- Aromatase inhibitor alone (Type: None): Aromatase inhibitor alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dienogest for Treatment of Adenomyotic Uteri

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 20-40 years~* Women with ultrasonographic evidence of adenomyosis~* Woman complains of vaginal bleeding or pelvic pain related to adenomyosis~Exclusion Criteria:~* Women with a history of malignancy or histological evidence of endometrial hyperplasia~* any adnexal abnormality on ultrasound~* undiagnosed vaginal~* contraindication to receive Vissane or gynera .

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Dienogest group (Type: ACTIVE_COMPARATOR): None
- Gynera group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete